Abstract: Objective The aim of this study was to investigate the antiviral efficacy of danoprevir and ravidasvir in the treatment of patients with chronic hepatitis C (CHC). Methods 84 patients with CHC were enrolled in our hospital between January 2021 and January 2023, and were divided into control and observation group, with 42 cases in each group, receiving pegylated interferon-α2b and ribavirin combination, or danoprevir and ravidasvir combination antiviral therapy for 12 w. All patients were followed-up for 24 weeks after discontinuation of the regimen. Serum HCV RNA load was measured by using fully automated viral load analysis system, and the rapidvirological response (RVR), end-treatment virological response (ETVR) and sustained virological responseat 12 weeks (SVR12) were recorded. Serum tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and IL-10 levelswere assayed by ELISA. Results TheRVR, ETVR and SVR12 in the observation group were 64.2%, 100.0% and 100.0%, all significantly higher than 42.8%, 69.0% and 54.8%(P<0.05)in the control; 24 weeks after discontinuation of the antiviral treatment, six patients (14.2%) in the control, but no patients (0.0%) in the observation relapsed(P<0.05); serum alanine aminotransferase and aspartate aminotransferase levels in the observation group were(32.5±8.4)U/L and (33.8±8.6)U/L, both significantly lower than [(54.2±8.7)U/L and (53.5±7.1)U/L, respectively, P<0.05] in the control; the while blood cell count, platelet count and hemoglobin concentration in the observation were (5.6±0.7)×10⁹/L, (108.1±18.9)×10⁹/L and (113.7±16.2)g/L, all significantly higher than [(3.5±0.6)×10⁹/L,(82.5±16.7)×10⁹/L and (96.8±13.9)g/L, respectively, P<0.05] in the control; serum TNF-α, IL-6 and IL-10 levels were (5.4±0.4)ng/L, (15.6±3.7)ng/L and (64.3±12.7)ng/L, all much lower than [(9.0±0.5)ng/L, (22.9±4.0)ng/L and (125.4±24.3)ng/L, respectively, P<0.05] in the control; during the antiviral treatment period, the incidence of untoward effects in the observation group was much lower than in the control (14.2% vs. 33.3%,P<0.05). Conclusion The combination of danoprevir and ravidasvir in the treatment of patients with CHC could quickly clear the viremia, has a promising antiviral efficacy, and warrants further clinical investigation.

Key words: Hepatitis C, Danoprevir, Ravidasvir, Efficacy, Therapy